|
Venous Ethanol for Ventricular Tachycardia
RECRUITINGPhase 2Sponsored by The Methodist Hospital Research Institute
Actively Recruiting
PhasePhase 2
SponsorThe Methodist Hospital Research Institute
Started2023-04-12
Est. completion2027-12-12
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT05511246
Summary
Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial
Eligibility
Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria: * Male and female, ages of 18 and 85 years and with a prior ICD implant * Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause) * One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG/cardiac monitor * Patients deemed candidates for RF ablation of VT * Able and willing to comply with pre-, post-, and follow-up requirements * Willing to sign the informed consent Exclusion Criteria: * Serum creatinine \>1.5 mg/dL, or creatinine clearance \<30 ml/min * Left ventricular (LV) ejection fraction ≤10% * Mobile LV thrombus on echocardiography * Absence of vascular access to the LV * Disease process likely to limit survival to \<12 months * New York Heart Association class IV heart failure * Cardiac surgery within the past 2 months (unless VT was incessant), * Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG) * Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia) * Severe aortic stenosis or mitral regurgitation with a flail leaflet * Pregnancy * Unwilling or unable to provide informed consent * Covid-19 positive testing within 14 days of randomization procedure * Enrolled, or planning to get enrolled, in another research study during his/her participation on the Velvet trial
Conditions3
Heart DiseaseIschemic CardiomyopathyVentricular Tachycardia
Locations1 site
Houston Methodist Hospital
Houston, Texas, 77030
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorThe Methodist Hospital Research Institute
Started2023-04-12
Est. completion2027-12-12
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT05511246